Fibromyalgia Treatment Market Size & Share, by Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants); Type (Symptomatic Treatment, Targeted Treatment); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

Request Free Sample Copy

Report ID: 4467
Published Date: Feb 27, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Fibromyalgia Treatment Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
AbbVie Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Aptinyx Inc.
Tonix Pharmaceuticals Holding Corp.
Virios Therapeutics

Browse Key Market Insights with Data Illustration:

Fibromyalgia Treatment Market Size & Share, Growth Forecasts 2033

In the News

Aptinyx Inc. declared the completion of the enrolment of 305 patients in the current Phase 2b study of NYX-2925 in fibromyalgia. NYX-2925 is being studied in 305 patients with fibromyalgia in a randomized, double-blind, placebo-controlled Phase 2 study.
Astellas Pharma Inc. has acquired bioelectronics start-up company Iota Biosciences, Inc. Astellas' Rx+ projects are estimated to accelerate in light of this acquisition.

Frequently Asked Questions (FAQ)

Worldwide growing incidences of road accidents, surge in post-traumatic stress disorder (PTSD), and worldwide boost in geriatric population are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2033.

Side effects associated with the use of fibromyalgia drugs, high adoption of generic drugs, and stringent regulations of government are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Aptinyx Inc., Tonix Pharmaceuticals Holding Corp., Virios Therapeutics, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, type, distribution channel, and by region.

The antiepileptic segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Companies Dominating the Fibromyalgia Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the fibromyalgia treatment market?

What would be the CAGR of fibromyalgia treatment market over the forecast period?

What are the challenges affecting the fibromyalgia treatment market growth?

Which region will provide more business opportunities for growth of fibromyalgia treatment market in future?

Who are the major players dominating the fibromyalgia treatment market?

How are the company profiles selected?

What are the segments in the fibromyalgia treatment market?

Which segment captures the largest market size in drug class segment in the fibromyalgia treatment market?